Blood Test May Improve Lung Cancer Screening

Blood Test May Improve Lung Cancer Screening
"This is a promising finding that can potentially improve the screening process, improve cancer outcomes, and reduce unnecessary interventions and associated morbidities," says Jussuf Kaifi.(MorphoBio/Shutterstock)

A blood test may help determine if nodules detected during CT scans are lung cancer, researchers report.

Annual screenings of patients at high risk for lung cancer can catch tumors early and improve a patient’s long-term prognosis. However, low-dose computer tomography (LDCT) has a high false-positive rate that can lead to unnecessary biopsies.

The researchers found a biomarker in the blood that can complement LDCT by distinguishing non-small-cell lung cancer (NSCLC) from benign nodules without an invasive biopsy.
“It’s a simple blood test that checks for two things: circulating tumor cells (CTCs) that detach from a primary tumor and circulate in the blood, and tumor-macrophage fusion (TMF) cells that have been determined to be highly prognostic for poor survival after lung cancer surgery,” says study author Jussuf Kaifi, a cancer surgeon at MU Health Care and an assistant professor of surgery at the University of Missouri School of Medicine.
Kaifi’s team collected blood samples from 221 patients, including 90 NSCLC patients, 74 high-risk screening patients with either no or benign nodules and 37 patients determined to have suspicious nodules detected by LDCT. Researchers also tested a control group of 20 people who had never smoked who were at low risk for lung cancer.

“When we collected the samples from the patients in our study, we found CTCs in all 90 patients with NSCLC, none of the patients in the control group, and in 29 of 37 patients with suspicious nodules,” Kaifi says. “We also found TMF cells in some NSCLC patients, and those were not present in patients with benign nodules.”

However, Kaifi’s team found that the rarity of TMF cells may make them unsuitable biomarkers for early cancer detection. Only 48% of patients with NSCLC tested positive for giant TMF cells. The next step is to conduct a prospective, large-scale, multicenter clinical trial to validate the role cellular liquid biomarkers play in improving diagnostic accuracy.

“This study demonstrated that integrating cellular liquid biomarkers, CTCs, and TMF cells into standardized LDCT screening protocols can improve accuracy of NSCLC detection in high-risk patients who have nodules detected by LDCT,” Kaifi says.

“This is a promising finding that can potentially improve the screening process, improve cancer outcomes, and reduce unnecessary interventions and associated morbidities.”
Their study appears in JCO Precision Oncology.

Research reported in this publication was supported by an Ellis Fischel Cancer Center Pilot Award and funding from the Department of Veterans Affairs. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

This article was originally published by University of Missouri. Republished via under Creative Commons License 4.0.
Related Topics